When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 21 Apr 2025
Last updated: 08 Aug 2024

Summary

Definition

History and exam

Key diagnostic factors

  • active symmetrical arthritis lasting >6 weeks
  • age 50 to 55 years
  • female sex
  • joint pain
  • joint swelling

Other diagnostic factors

  • morning stiffness
  • swan neck deformity
  • Boutonniere's deformity
  • ulnar deviation
  • rheumatoid nodules
  • vasculitic lesions
  • pleuritic chest pain
  • scleritis and/or uveitis

Risk factors

  • genetic predisposition
  • smoking
  • overweight or obesity
  • infection

Diagnostic investigations

1st investigations to order

  • rheumatoid factor (RF)
  • anti-cyclic citrullinated peptide (anti-CCP) antibody
  • radiographs
  • ultrasonography

Treatment algorithm

Contributors

Authors

Yusuf Yazici, MD
Yusuf Yazici

Clinical Associate Professor of Medicine

New York University School of Medicine

New York

NY

Disclosures

YY receives research support from BMS and Amgen; he has consulted for Amgen, BMS, Hemay, Chugai, and Sanofi.

Peer reviewers

Joshua F. Baker, MD, MSCE

Associate Professor of Medicine and Epidemiology

University of Pennsylvania

Pennsylvania

PA

Disclosures

JFB has received consulting fees from Bristol-Myers Squibb, Pfizer, Cumberland Pharma, and CorEvitas.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-23.Full text  Abstract

National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. Oct 2020 [internet publication].Full text

Smolen JS, Landewé RBM, Bergstra SA, eta al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18 Epub 2022 Nov 10.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer